---
document_datetime: 2026-02-20 15:55:00
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/osqay-epar-all-authorised-presentations_en.pdf
document_name: osqay-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.7398349
conversion_datetime: 2026-02-21 12:45:05.38211
docling_version:
  docling-serve: 1.13.0
  docling-jobkit: 1.11.0
  docling: 2.74.0
  docling-core: 2.65.1
  docling-ibm-models: 3.11.0
  docling-parse: 5.3.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.3-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical Form    | Route of Administration   | Immediate Packaging        | Content (concentration)   | Pack size            |
|------------------|-------------------|------------|------------------------|---------------------------|----------------------------|---------------------------|----------------------|
| EU/1/25/1997/001 | Osqay             | 60 mg      | Solution for injection | Subcutaneous use          | pre-filled syringe (glass) | 1 ml (60 mg/ml)           | 1 pre-filled syringe |